悦心健康
(002162)
| 流通市值：32.82亿 | | | 总市值：32.85亿 |
| 流通股本：9.19亿 | | | 总股本：9.20亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 888,897,808.68 | 558,526,815.52 | 221,095,436.83 | 1,278,144,047 |
| 营业收入 | 888,897,808.68 | 558,526,815.52 | 221,095,436.83 | 1,278,144,047 |
| 二、营业总成本 | 912,768,563.09 | 558,570,295.57 | 235,210,331.67 | 1,287,721,593.93 |
| 营业成本 | 700,788,490.68 | 429,182,310.51 | 174,172,301.6 | 991,286,715.48 |
| 税金及附加 | 9,571,249.75 | 5,438,431.57 | 2,400,975.1 | 13,415,563.36 |
| 销售费用 | 125,399,345.99 | 79,888,353.66 | 37,371,556.19 | 173,798,033.39 |
| 管理费用 | 56,358,628.21 | 30,521,483.67 | 14,861,503.71 | 76,880,743.63 |
| 研发费用 | 5,860,659.43 | 3,694,163.6 | 1,475,305.52 | 10,207,286.32 |
| 财务费用 | 14,790,189.03 | 9,845,552.56 | 4,928,689.55 | 22,133,251.75 |
| 其中:利息费用 | 18,199,003.17 | 12,081,760.21 | 5,932,319.81 | 27,041,616.37 |
| 其中:利息收入 | 4,250,415.68 | 2,760,481.98 | 1,420,920.08 | 5,632,150.51 |
| 加:公允价值变动收益 | 1,488,200 | 1,488,200 | - | -728,000 |
| 加:投资收益 | -3,930,780.88 | -4,743,621.26 | -1,466,388.87 | 162,347,667.94 |
| 资产处置收益 | - | - | - | -260,317.88 |
| 资产减值损失(新) | -5,027,045.17 | -5,027,045.17 | - | -40,864,881.16 |
| 信用减值损失(新) | -4,176,271.2 | 11,462,036.6 | - | -78,832,029.62 |
| 其他收益 | 4,515,745.21 | 3,902,882.04 | 1,416,495.58 | 10,057,507.38 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -31,000,906.45 | 7,038,972.16 | -14,164,788.13 | 42,142,399.73 |
| 加:营业外收入 | 1,048,556.47 | 876,575.11 | 481,992.98 | 1,656,289.44 |
| 减:营业外支出 | 371,409.83 | 91,291.55 | 86,591.87 | 4,377,013.3 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -30,323,759.81 | 7,824,255.72 | -13,769,387.02 | 39,421,675.87 |
| 减:所得税费用 | 5,437,824.01 | 6,680,468.11 | 29,740.35 | -8,611,542.43 |
| 六、净利润 | -35,761,583.82 | 1,143,787.61 | -13,799,127.37 | 48,033,218.3 |
| 持续经营净利润 | -33,359,977.16 | 2,824,712.32 | -13,160,030.62 | 62,099,593.19 |
| 终止经营净利润 | -2,401,606.66 | -1,680,924.71 | -639,096.75 | -14,066,374.89 |
| 归属于母公司股东的净利润 | -33,072,851.16 | 2,428,896.87 | -13,017,355.44 | 50,063,818.15 |
| 少数股东损益 | -2,688,732.66 | -1,285,109.26 | -781,771.93 | -2,030,599.85 |
| (一)基本每股收益 | -0.04 | 0 | -0.01 | 0.05 |
| (二)稀释每股收益 | -0.04 | 0 | -0.01 | 0.05 |
| 八、其他综合收益 | -26,355.54 | -6,350.16 | -1,166.05 | -9,261.82 |
| 归属于母公司股东的其他综合收益 | -15,813.33 | -3,810.1 | -699.63 | -5,557.09 |
| 九、综合收益总额 | -35,787,939.36 | 1,137,437.45 | -13,800,293.42 | 48,023,956.48 |
| 归属于母公司股东的综合收益总额 | -33,088,664.49 | 2,425,086.77 | -13,018,055.07 | 50,058,261.06 |
| 归属于少数股东的综合收益总额 | -2,699,274.87 | -1,287,649.32 | -782,238.35 | -2,034,304.58 |
| 公告日期 | 2024-10-26 | 2024-08-27 | 2024-04-26 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |